En este video, la Dra. Velázquez Mañana analiza las mutaciones del EGFR, los diferentes subtipos de cáncer de pulmón y cómo determinar cuál es el mejor tratamiento en general. To watch the complete playlist, click here. Special thanks to Genentech, BMS, Takeda, Johnson & Johnson, and Daiichi-Sankyo

In this Program, Drs. Arya Mariam Roy, Assistant Professor at The Ohio State University, Erick Saldanha, Medical Oncologist & Postdoctoral Clinical Fellow at Princess Margaret Cancer Centre, Guilherme Sacchi de Camargo Correia, Hematology and Oncology fellow at Mayo Clinic in Jacksonville, Florida

The Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón presentado el 9 de agosto de 2025 has now ended. ¡Los vídeos están disponibles BAJO DEMANDA! Las versiones completas sin editar del Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón de agosto de 2025 ya están disponibles BAJO

Como parte de la Videoteca de Cáncer de Pulmón en Español 2023, el Dr. Alejandro R. Calvo, MD, FACP, aborda temas relacionados con el cáncer de pulmón, desde el diagnóstico hasta las opciones de tratamiento, y preguntas y conceptos erróneos comunes. Para ver la serie completa de click aquí.

The 2025 Targeted Therapies in Lung Cancer Patient Forum was a live, virtual, interactive patient education event presented in March 2025 and led by Dr. Lyudmila Bazhenova. It included presentations and panel discussions from 11 top medical professionals covering educational topics related to

Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra

For our Mandarin speaking community, Jenny J. Li, MD, Hematology/Oncology Fellow at the Mayo Clinic in Rochester MN, offers translated updates to our Lung Cancer Video Library. In this video translation, Dr. Li discusses evolving standards for molecular testing in advanced NSCLC. We would like to

We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish speaking community. Translating Molecular Oncology Results into Targeted Therapy Treatment For the newest additions to our Lung Cancer Video Library, produced in Spanish for our Latino Community, Dr. Luis E. Raez

We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish speaking community. Para conocer las adiciones más recientes a nuestra Biblioteca de videos sobre cáncer de pulmón, producida en español para nuestra comunidad latina, el Dr. Luis E. Raez nos brinda la

For this new addition to the GRACE Lung Cancer Video Library, Dr. Charu Aggarwal joins GRACE to discuss current updates in non small cell lung cancer. In this video, Dr. Aggarwal discusses updated information on the utility of liquid biopsies. To join the conversation, visit https://cancergrace.org

Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, describes the types of situations in which local therapy is appropriate for treating limited acquired resistance.

Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.

Dr. Ross Camidge, University of Colorado, discusses management of CNS progression for ALK-positive NSCLC including monitoring frequency and preferences between systemic and radiation therapy.

Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.

Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.